+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Autoimmune Disease Drugs Market - Global Forecast 2026-2032- Product Image
Autoimmune Disease Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Autoimmune Disease Drugs Market - Global Forecast 2026-2032

  • Report

  • 195 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904622
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Autoimmune Disease Drugs Market is projected to reach USD 135.64 Billion in 2026. It is expected to continue growing at a CAGR of 8.45%, reaching USD 222.19 Billion by 2032.

The autoimmune disease drugs market is anchored by chronic, immune-mediated conditions such as rheumatoid arthritis, psoriasis, psoriatic arthritis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, type 1 diabetes, and autoimmune thyroid disorders. More than 80 autoimmune diseases are recognized in medical literature, and many require long-term pharmacologic management, creating sustained demand for immunosuppressants, corticosteroids, conventional disease-modifying antirheumatic drugs, biologics, biosimilars, and targeted small molecules.

Market momentum is being shaped by earlier diagnosis, expanding specialist access, rising use of treat-to-target protocols, and continued innovation in cytokine inhibition, B-cell modulation, T-cell pathways, complement inhibition, Janus kinase inhibition, sphingosine-1-phosphate receptor modulation, and emerging Bruton tyrosine kinase inhibitors. At the same time, payer pressure, biosimilar competition, safety monitoring, and real-world evidence requirements are redefining how autoimmune disease drugs are developed, priced, prescribed, and reimbursed.

Transformative Shifts in the Autoimmune Treatment Landscape

The autoimmune treatment landscape is moving from broad immune suppression toward precision immunology, where therapies are increasingly selected according to disease phenotype, biomarker profile, prior treatment response, comorbidity risk, and route-of-administration preference. Biologics remain central in high-value autoimmune therapy categories, while biosimilars are reshaping competition in established segments such as tumor necrosis factor inhibitors and other monoclonal antibody classes.

Transformative shifts include stronger adoption of self-injectable and oral targeted therapies, growing post-marketing safety oversight for JAK inhibitors and other immunomodulators, and rising payer demand for comparative effectiveness evidence. Manufacturers are also adapting to decentralized clinical trials, patient support programs, specialty pharmacy models, and value-based contracting, all of which influence market access, adherence, and brand durability.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative value across autoimmune disease drug discovery, clinical development, commercialization, and pharmacovigilance. AI-enabled analytics can identify immune pathway targets, mine genomic and proteomic datasets, model disease progression, and support patient stratification in heterogeneous conditions such as systemic lupus erythematosus, inflammatory bowel disease, psoriasis, rheumatoid arthritis, and multiple sclerosis.

The strongest impact is emerging where AI improves trial feasibility, enriches responder populations, accelerates safety signal detection, and converts real-world data into actionable evidence for regulators, payers, clinicians, and patients. Responsible adoption requires transparent models, bias assessment, data privacy controls, and clinical validation, particularly because autoimmune diseases disproportionately affect women and often present with variable symptoms across ancestry groups, age cohorts, and care settings.

Key Regional Insights

North America remains a leading region for autoimmune disease drugs due to strong specialty care infrastructure, advanced biologic use, FDA innovation pathways, and broad clinical trial activity, with the United States driving most regional demand and Canada emphasizing structured reimbursement review. Europe combines high diagnosis rates, EMA oversight, established clinical guidelines, and mature health technology assessment systems, while biosimilar adoption is particularly important in cost containment across major European Union markets and the United Kingdom.

Asia-Pacific is expanding rapidly as China, Japan, India, South Korea, and Australia invest in biologics, biosimilars, local manufacturing, clinical research capacity, and broader access to specialty medicines. Latin America, led by Brazil and Mexico, is improving access through public procurement and private insurance channels, although affordability, reimbursement consistency, and specialist availability remain constraints. The Middle East, especially GCC markets, is increasing biologic uptake through hospital modernization, national health strategies, and specialty care investment, while Africa continues to face access gaps linked to diagnostic capacity, rheumatology and immunology specialist shortages, cold-chain limitations, and reimbursement constraints.

Key Group Insights

The G7 continues to anchor high-value autoimmune drug innovation through advanced research ecosystems, experienced regulatory agencies, strong pharmacovigilance systems, and large specialty pharmaceutical markets. The European Union plays a central role in biosimilar policy, centralized approvals, health technology assessment alignment, real-world evidence standards, and cross-border pharmacovigilance, supporting both innovation and cost efficiency across member states.

BRICS countries are increasingly important for patient access expansion, local biologics production, biosimilar development, and clinical trial diversification, with China, India, and Brazil standing out for scale and manufacturing capacity. ASEAN markets are progressing through broader healthcare coverage, improving diagnostic pathways, and better specialist access, although reimbursement depth varies widely across member countries. GCC countries are investing in premium care infrastructure, digital health, biologic access, and centralized procurement capabilities, while NATO is not a healthcare market bloc but includes countries prioritizing medicine supply resilience, procurement security, emergency preparedness, and biopharmaceutical manufacturing continuity.

Key Country Insights

The United States is the largest commercial opportunity within autoimmune disease drugs, supported by specialist prescribing, biologic penetration, rapid uptake of novel therapies, robust clinical trial participation, and extensive real-world evidence generation, while Canada emphasizes evidence-based reimbursement, health technology review, and provincial formulary access. Mexico and Brazil are expanding autoimmune treatment capacity but remain sensitive to affordability, public procurement, biosimilar availability, and continuity of specialty care. In Europe, the United Kingdom, Germany, France, Italy, and Spain combine high clinical standards with strict pricing and health technology assessment scrutiny, while Russia presents access variability tied to reimbursement coverage, local supply dynamics, and regulatory conditions.

China is accelerating biologics and biosimilars through regulatory reform, domestic innovation, and broader hospital access, while India is a major growth market for cost-effective therapies, biosimilars, and local manufacturing. Japan remains a sophisticated market with strong specialty care, high regulatory standards, and an aging population that influences autoimmune and inflammatory disease management. Australia benefits from structured public reimbursement and evidence-based access pathways, and South Korea combines advanced healthcare infrastructure with competitive biosimilar development, high digital health adoption, and export-oriented biopharmaceutical capabilities.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated mechanisms of action, validated biomarkers, and patient segmentation strategies that improve outcomes beyond established biologics and conventional disease-modifying therapies. Organizations competing in mature categories need biosimilar-aware lifecycle planning, including device innovation, adherence support, real-world evidence generation, and clear positioning for patients who fail, relapse on, or cannot tolerate first-line therapies.

Commercial success will depend on early payer engagement, robust pharmacoeconomic evidence, scalable patient assistance programs, and region-specific access strategies aligned with local reimbursement rules and clinical practice patterns. Leaders should also invest in AI governance, diverse clinical trial recruitment, supply chain resilience, cold-chain reliability, and post-marketing surveillance to strengthen trust with regulators, clinicians, payers, and patients.

Research Methodology

This executive summary is developed through a structured research methodology that triangulates regulatory approvals, clinical trial registries, peer-reviewed literature, health technology assessment outputs, public health sources, treatment guidelines, pharmacovigilance updates, and market access intelligence. Sources commonly assessed include the FDA, EMA, national regulatory agencies, ClinicalTrials.gov, WHO-linked public health data, OECD health indicators, and leading rheumatology, dermatology, neurology, endocrinology, and gastroenterology guidance.

The analysis evaluates therapy class dynamics, disease-area demand signals, regional access conditions, competitive positioning, pricing pressure, pipeline maturity, biosimilar penetration, regulatory developments, safety trends, and evidence-generation requirements. Findings are synthesized to identify durable market drivers, constraints, and strategic implications for stakeholders across the autoimmune disease drugs value chain, while avoiding unsupported market sizing or forecasting assumptions.

Conclusion

The autoimmune disease drugs market is entering a more competitive and evidence-driven phase, where scientific innovation must be matched by access, safety, affordability, and real-world performance. Biologics and targeted small molecules will continue to transform outcomes across immune-mediated disorders, while biosimilars, health technology assessment scrutiny, and payer controls will reshape pricing, reimbursement, and treatment sequencing.

Organizations that combine precision immunology, AI-enabled development, strong pharmacovigilance, differentiated delivery formats, and localized market access strategies will be best positioned to strengthen performance. The most durable opportunities will emerge in therapies that demonstrate sustained disease control, improved quality of life, convenient administration, safety confidence, and measurable value across diverse healthcare systems.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Autoimmune Disease Drugs Market, by Drug Class
7.1. Introduction
7.2. Biologics
7.2.1. Fusion Proteins
7.2.2. Monoclonal Antibodies
7.2.3. Peptides
7.3. Biosimilars
7.4. Small Molecules
8. Autoimmune Disease Drugs Market, by Mechanism Of Action
8.1. Introduction
8.2. B Cell Depleting Agents
8.3. Il Inhibitors
8.3.1. Il17 Inhibitors
8.3.2. Il23 Inhibitors
8.3.3. Il6 Inhibitors
8.4. Jak Inhibitors
8.4.1. Jak1 Inhibitors
8.4.2. Jak1/2 Inhibitors
8.4.3. Jak3 Inhibitors
8.5. Tnf Inhibitors
9. Autoimmune Disease Drugs Market, by Route Of Administration
9.1. Introduction
9.2. Oral
9.2.1. Capsule
9.2.2. Solution
9.2.3. Tablet
9.3. Parenteral
9.3.1. Intravenous
9.3.2. Subcutaneous
10. Autoimmune Disease Drugs Market, by Indication
10.1. Introduction
10.2. Inflammatory Bowel Disease
10.2.1. Crohn's Disease
10.2.2. Ulcerative Colitis
10.3. Lupus
10.4. Multiple Sclerosis
10.5. Psoriasis
10.5.1. Plaque Psoriasis
10.5.2. Psoriatic Arthritis
10.6. Rheumatoid Arthritis
11. Autoimmune Disease Drugs Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Homecare Settings
11.4. Hospitals
12. Autoimmune Disease Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Offline
12.3. Online
13. Autoimmune Disease Drugs Market, by Region
13.1. Asia-Pacific
13.2. North America
13.3. Latin America
13.4. Europe
13.5. Middle East
13.6. Africa
14. Autoimmune Disease Drugs Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Autoimmune Disease Drugs Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Abbott Laboratories
17.2. Astellas Pharma Inc.
17.3. AstraZeneca PLC
17.4. Baxter International, Inc.
17.5. Bayer AG
17.6. Biocon Limited
17.7. Bioton S.A.
17.8. Boehringer Ingelheim International GmbH
17.9. Bristol-Myers Squibb Company
17.10. Eli Lilly and Company
17.11. Eva Pharma
17.12. GlaxoSmithKline PLC
17.13. Glenmark Pharmaceuticals Limited
17.14. Gulf Pharmaceutical Industries (Julphar)
17.15. Johnson & Johnson Services, Inc.
17.16. Lupin Limited
17.17. MannKind Corporation
17.18. Merck & Co., Inc.
17.19. MJ Biopharm Pvt. Ltd.
17.20. Novartis AG
17.21. Novo Nordisk A/S
17.22. Oramed Pharmaceuticals Inc.
17.23. Pfizer Inc.
17.24. Sanofi S.A.
17.25. Takeda Pharmaceutical Company Limited
17.26. Tonghua Dongbao Pharmaceutical Co., Ltd.
17.27. Viatris Inc.
17.28. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL FUSION PROTEINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL FUSION PROTEINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL PEPTIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL PEPTIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL PEPTIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL BIOSIMILARS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL B CELL DEPLETING AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL B CELL DEPLETING AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL B CELL DEPLETING AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL IL INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL IL INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL IL INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL IL17 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL IL17 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL IL17 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL IL23 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL IL23 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL IL23 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL IL6 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL IL6 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL IL6 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL JAK INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL JAK INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL JAK INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL JAK1 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL JAK1 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL JAK1 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL JAK1/2 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL JAK1/2 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL JAK1/2 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL JAK3 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL JAK3 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL JAK3 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL TNF INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL TNF INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL CAPSULE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL CAPSULE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL CAPSULE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL SOLUTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL SOLUTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL SOLUTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL TABLET MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL TABLET MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL TABLET MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL CROHN'S DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL CROHN'S DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL CROHN'S DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL LUPUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL LUPUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL LUPUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL PSORIASIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL PSORIASIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL PSORIASIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL PLAQUE PSORIASIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL PLAQUE PSORIASIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL PLAQUE PSORIASIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL PSORIATIC ARTHRITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL PSORIATIC ARTHRITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL PSORIATIC ARTHRITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2017-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2017-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 128. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2017-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 135. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 136. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 137. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 138. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 139. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2017-2032 (USD MILLION)
TABLE 140. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2017-2032 (USD MILLION)
TABLE 141. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 142. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 143. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 144. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 145. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 146. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2017-2032 (USD MILLION)
TABLE 147. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 148. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 149. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 150. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 151. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 152. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 153. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2017-2032 (USD MILLION)
TABLE 154. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2017-2032 (USD MILLION)
TABLE 155. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 156. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 157. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 158. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 159. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 160. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2017-2032 (USD MILLION)
TABLE 161. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 162. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 163. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 164. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 165. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 166. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 167. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2017-2032 (USD MILLION)
TABLE 168. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2017-2032 (USD MILLION)
TABLE 169. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 170. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 171. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 172. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 173. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 174. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2017-2032 (USD MILLION)
TABLE 175. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 176. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 177. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 178. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 179. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 180. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 181. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2017-2032 (USD MILLION)
TABLE 182. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2017-2032 (USD MILLION)
TABLE 183. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 184. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 185. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 186. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 187. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 188. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2017-2032 (USD MILLION)
TABLE 189. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 190. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 191. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 192. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 193. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 194. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 195. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2017-2032 (USD MILLION)
TABLE 196. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2017-2032 (USD MILLION)
TABLE 197. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 198. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 199. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 200. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 201. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 202. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2017-2032 (USD MILLION)
TABLE 203. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 204. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 205. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 206. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 207. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 208. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 209. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 210. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2017-2032 (USD MILLION)
TABLE 211. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2017-2032 (USD MILLION)
TABLE 212. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 213. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 214. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 215. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 216. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 217. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2017-2032 (USD MILLION)
TABLE 218. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 219. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 220. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 221. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 222. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 223. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 224. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2017-2032 (USD MILLION)
TABLE 225. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2017-2032 (USD MILLION)
TABLE 226. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 227. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 228. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 229. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 230. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 231. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2017-2032 (USD MILLION)
TABLE 232. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 233. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 234. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 235. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 236. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 237. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 238. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2017-2032 (USD MILLION)
TABLE 239. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2017-2032 (USD MILLION)
TABLE 240. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 241. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 242. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 243. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 244. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 245. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2017-2032 (USD MILLION)
TABLE 246. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 247. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 248. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 249. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 250. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 251. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 252. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2017-2032 (USD MILLION)
TABLE 253. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2017-2032 (USD MILLION)
TABLE 254. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 255. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 256. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 257. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 258. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 259. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2017-2032 (USD MILLION)
TABLE 260. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 261. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 262. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 263. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 264. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 265. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 266. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2017-2032 (USD MILLION)
TABLE 267. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2017-2032 (USD MILLION)
TABLE 268. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 269. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 270. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 271. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 272. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 273. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2017-2032 (USD MILLION)
TABLE 274. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 275. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 276. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 277. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 278. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 279. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 280. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2017-2032 (USD MILLION)
TABLE 281. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2017-2032 (USD MILLION)
TABLE 282. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 283. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 284. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 285. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 286. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 287. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2017-2032 (USD MILLION)
TABLE 288. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 289. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 290. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 291. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 292. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 293. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 294. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 295. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2017-2032 (USD MILLION)
TABLE 296. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2017-2032 (USD MILLION)
TABLE 297. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 298. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 299. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 300. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 301. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 302. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2017-2032 (USD MILLION)
TABLE 303. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 304. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 305. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 306. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 307. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 308. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 309. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2017-2032 (USD MILLION)
TABLE 310. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2017-2032 (USD MILLION)
TABLE 311. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 312. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 313. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 314. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 315. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 316. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2017-2032 (USD MILLION)
TABLE 317. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 318. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 319. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 320. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 321. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 322. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 323. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2017-2032 (USD MILLION)
TABLE 324. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2017-2032 (USD MILLION)
TABLE 325. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 326. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 327. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 328. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 329. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 330. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2017-2032 (USD MILLION)
TABLE 331. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 332. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 333. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 334. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 335. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 336. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 337. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2017-2032 (USD MILLION)
TABLE 338. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2017-2032 (USD MILLION)
TABLE 339. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 340. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 341. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 342. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 343. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2017-2032 (USD MILLION)
TABLE 344. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2017-2032 (USD MILLION)
TABLE 345. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 346. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 347. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 348. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 349. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 350. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 351. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2017-2032 (USD MILLION)
TABLE 352. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2017-2032 (USD MILLION)
TABLE 353. UNITED KINGDOM AUTOIMMUNE DISEASE DR

Companies Mentioned

  • Abbott Laboratories
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Bayer AG
  • Biocon Limited
  • Bioton S.A.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Eva Pharma
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Gulf Pharmaceutical Industries (Julphar)
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • MannKind Corporation
  • Merck & Co., Inc.
  • MJ Biopharm Pvt. Ltd.
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages195
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 135.64 Billion
Forecasted Market Value ( USD ) by 2032 $ 222.19 Billion
Compound Annual Growth Rate8.4%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

Autoimmune Disease Therapeutics Market - Global Forecast 2026-2032 - Product Image

Autoimmune Disease Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Celiac Disease Drugs Market - Global Forecast 2026-2032 - Product Image

Celiac Disease Drugs Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Autoimmune Disease Therapeutics - Global Strategic Business Report - Product Image

Autoimmune Disease Therapeutics - Global Strategic Business Report

  • Report
  • 368 Pages
  • Global
From
Methotrexate Drugs - Global Strategic Business Report - Product Image

Methotrexate Drugs - Global Strategic Business Report

  • Report
  • 564 Pages
  • Global
From
JAK Inhibitors - Competitive Landscape, 2026 - Product Image

JAK Inhibitors - Competitive Landscape, 2026

  • Report
  • 180 Pages
  • Global
From

About the Autoimmune Disease Drug Market

The Autoimmune Disease Drug market is a subset of the Immune Disorders Drugs market, which focuses on treatments for diseases caused by an overactive immune system. These drugs are used to reduce inflammation, suppress the immune system, and prevent the body from attacking its own tissues. Common autoimmune diseases include rheumatoid arthritis, psoriasis, lupus, and multiple sclerosis. Autoimmune Disease Drugs are typically divided into two categories: biologics and small molecules. Biologics are large, complex molecules derived from living organisms, while small molecules are chemically synthesized. Both types of drugs are used to treat autoimmune diseases, but biologics are more effective and have fewer side effects. The Autoimmune Disease Drug market is highly competitive, with many companies developing and marketing drugs for the treatment of autoimmune diseases. Some of the major players in the market include AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Roche. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.